The S&P 500 soared more than 32% in 2013, and several big pharma companies, namely Bristol-Myers Squibb (BMY -0.93%), AbbVie (ABBV -0.09%), Roche (RHHBY -0.83%), Johnson & Johnson (JNJ 0.09%), and AstraZeneca (AZN -0.06%) also performed extraordinarily well. The following slideshow reveals why these companies beat out their big pharma peers and what drove their strong performances in 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The pharmaceutical sector had a stellar 2013, but which stocks were the best?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, ImmunoGen, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Johnson & Johnson
JNJ
$190.90
(0.09%)
$0.18
Bristol Myers Squibb
BMY
$43.55
(-0.93%)
$0.41
Roche Holding AG
RHHBY
$45.28
(-0.83%)
$0.38
AstraZeneca Plc
AZN
$84.48
(-0.06%)
$0.05
AbbVie
ABBV
$230.30
(-0.09%)
$0.20
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Scholar Rock Stock Got Socked on Monday
Down 44%, Should You Buy the Dip on Viking Therapeutics?
2 Dividend Stocks to Double Up on Right Now
Where Will Pfizer Be in 5 Years?
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.